Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3049% below fair value
$1.09−0.15 (-11.74%)
Close on Nov 18, 2026Market cap $5.01MP/E –Yield –
Biomerica operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Biomerica's operating income for the twelve months ending Aug 31, 2026 was -$5.43M. For fiscal 2026 it was -$5.32M. The highest annual figure on record is $514.01K in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | -$5.32M | – |
| FY2025 | May 31, 2025 | -$5.14M | – |
| FY2024 | May 31, 2024 | -$6.37M | – |
| FY2023 | May 31, 2023 | -$7.22M | – |
| FY2022 | May 31, 2022 | -$4.53M | – |
| FY2021 | May 31, 2021 | -$7.50M | – |
| FY2020 | May 31, 2020 | -$2.74M | – |
| FY2019 | May 31, 2019 | -$2.41M | – |
| FY2018 | May 31, 2018 | -$1.48M | – |
| FY2017 | May 31, 2017 | -$954.63K | – |
| FY2016 | May 31, 2016 | -$826.95K | – |
| FY2015 | May 31, 2015 | -$670.60K | – |
| FY2014 | May 31, 2014 | -$446.59K | -186.9% |
| FY2013 | May 31, 2013 | $514.01K | +1.8% |
| FY2012 | May 31, 2012 | $505.00K | – |
| FY2011 | May 31, 2011 | -$132.26K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -$1.23M | – |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -$1.53M | – |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -$1.30M | – |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -$1.37M | – |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | -$1.12M | – |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -$1.56M | – |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -$1.21M | – |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -$993.00K | – |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -$1.37M | – |
| Q4 FY2024CQ2 2024 | May 31, 2024 | -$1.53M | – |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$2.00M | – |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -$1.61M | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | -$1.23M | – |
| Q4 FY2023CQ2 2023 | May 31, 2023 | -$1.84M | – |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | -$1.65M | – |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$1.67M | – |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -$2.07M | – |
| Q4 FY2022CQ2 2022 | May 31, 2022 | -$1.76M | – |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | -$107.50K | – |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | -$1.13M | – |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | -$1.54M | – |
| Q4 FY2021CQ2 2021 | May 31, 2021 | -$1.72M | – |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -$2.17M | – |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | -$1.71M | – |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | -$1.90M | – |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -$825.98K | – |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | -$914.89K | – |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | -$489.74K | – |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | -$509.56K | – |
| Q4 FY2019CQ2 2019 | May 31, 2019 | -$764.82K | – |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | -$707.25K | – |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | -$485.94K | – |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | -$454.79K | – |
| Q4 FY2018CQ2 2018 | May 31, 2018 | -$644.14K | – |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | -$322.85K | – |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | -$288.74K | – |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | -$226.03K | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | -$351.45K | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | -$317.72K | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | -$219.54K | – |
See a number that looks wrong?